Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26128974 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPK1HTTMAPTTHRB | |
| SCHEMBL2711110 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL2713437 | 0.83 | CYP1A2 (0.58) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL26129852 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL29968906 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL26131334 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL26590315 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL29969191 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL3434191 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTMAPTCYP1A2 | |
| SCHEMBL31013246 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPK1 1184/4885HTT 2506/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPK1 1184/4885HTT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.